1,539 results on '"Morgan, Gareth"'
Search Results
2. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial
3. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
4. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
5. Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation
6. Young and Distinct: Clinical Characteristics and Outcomes of Patients 50 or Younger with Multiple Myeloma
7. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
8. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
9. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
10. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
11. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
12. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
13. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
14. Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
15. Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial
16. Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
17. The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma
18. Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma
19. Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
20. Mapping and Modelling the Molecular Mechanisms That Drive Clonal Plasma Cell-Derived Amyloidogenic Light Chain Induced Cardiotoxicity
21. Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
22. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
23. The Frequency of Alternative Splicing in Multiple Myeloma Is Determined By the Non-Homologous End Joining Pathway
24. Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
25. Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
26. Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
27. The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
28. The Mutagenic Impact of Radiotherapy in Multiple Myeloma
29. Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
30. Curing myeloma at last: defining criteria and providing the evidence
31. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma
32. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
33. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
34. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
35. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
36. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
37. IMWG consensus on maintenance therapy in multiple myeloma
38. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
39. Redefining nonmeasurable multiple myeloma using mass spectrometry
40. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
41. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
42. A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma
43. N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma
44. Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)
45. Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy
46. Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms
47. Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
48. Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies
49. Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform
50. Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.